This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Pamela Taulbee

Senior writer, health care, The Deal (Washington, D.C.)

Pamela Taulbee
By This Author:
« Back
Page 1 of 1
Next »
Article

Mallinckrodt Acquires Questcor for $5.6B

By Pamela Taulbee

Irish specialty pharma plans to take California target's Acthar gel international.

11:57AM 04/07/14

Article

Brookdale, Emeritus Create Senior Living Behemoth

By Pamela Taulbee

Brookdale Senior Living and Emeritus are merging to create the first national senior living services company, with business in 46 states, the companies said Thursday.

12:09PM 02/21/14

Article

Catalent leads parade of drugmakers headed to market

By Pamela Taulbee

Nearly two dozen healthcare companies, mostly biotechs, are expected to price in the next few weeks.

12:50PM 01/29/14

Article

NuPathe Picks Teva as Merger Partner

By Pamela Taulbee

Teva Pharmaceutical Industries won a bid to purchase Malvern, Pa.-based NuPathe with an offer that came in at only $9 million more than its M&A rival, Endo Health Solutions.

12:43PM 01/21/14

Article

The Deal: Forest Widens Business, Pays $2.9 Billion for Aptalis

By Pamela Taulbee

Forest Laboratories is shoring up its gastrointestinal business and gaining a cystic fibrosis business in Europe with the acquisition of Aptalis Holdings.

02:06PM 01/08/14

« Back
Page 1 of 1
Next »

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 +2.54 0.14%
NASDAQ 4,095.5160 +9.2910 0.23%

Brokerage Partners

Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs